Since the 2001 update of the American Heart Association (AHA)/American College of Cardiology (ACC) consensus statement on secondary prevention, important evidence from clinical trials has emerged that further supports and broadens the merits of aggressive risk-reduction therapies for patients with established coronary and other atherosclerotic vascular disease, including peripheral arterial disease, atherosclerotic aortic disease, and carotid artery disease. This growing body of evidence confirms that aggressive comprehensive risk factor management improves survival, reduces recurrent events and the need for interventional procedures, and improves quality of life for these patients.

Compelling evidence from recent clinical trials and revised practice guidelines provided the impetus for this update of the 2001 recommendations with evidence-based results (Table 1). Classification of Recommendations and Level of Evidence are expressed in ACC/AHA format, as detailed in Tables 2 and 3. Recommendations made herein are based largely on major practice guidelines from the National Institutes of Health and ACC/AHA. In many cases, these practice guidelines were supplemented by research findings published after the publication of the primary reference(s). Thus, the development of the present statement involved a process of partial adaptation of other guideline statements and reports and supplemental literature searches. For specific search criteria, see the Appendix. The findings from additional lipid reduction trials involving more than 50,000 patients resulted in new optional therapeutic targets, which were outlined in the 2004 update of the National Heart, Lung, and Blood Institute’s Adult Treatment Panel (ATP) III report. These changes defined optional lower target cholesterol levels for very high-risk coronary heart disease (CHD) patients, especially those with acute coronary syndromes, and expanded indications for drug treatment. Subsequent to the 2004 update of ATP III, 2 additional trials demonstrated cardiovascular benefit for lipid lowering significantly below current cholesterol goal levels for those with chronic CHD. These new trials allow for alterations in guidelines, such that low-density lipoprotein cholesterol (LDL-C) should be <100 mg/dL for all patients with CHD and other clinical forms of atherosclerotic disease, but in addition, it is reasonable to treat to LDL-C <70 mg/dL in such patients. When the
**TABLE 1. AHA/ACC Secondary Prevention for Patients With Coronary and Other Vascular Disease*: 2006 Update**

<table>
<thead>
<tr>
<th>Intervention Recommendations With Class of Recommendation and Level of Evidence</th>
<th>SMOKE:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Goal</strong></td>
<td>Complete cessation. No exposure to environmental tobacco smoke.</td>
</tr>
<tr>
<td><strong>Women</strong></td>
<td>Waist circumference: men &lt;35 inches, women &lt;40 inches, or &lt;130/80 mm Hg if patient has diabetes or chronic kidney disease.</td>
</tr>
<tr>
<td><strong>Men</strong></td>
<td>Body mass index: 18.5 to 24.9 kg/m².</td>
</tr>
<tr>
<td><strong>Women</strong></td>
<td>Body mass index: 18.5 to 24.9 kg/m².</td>
</tr>
<tr>
<td><strong>Goal</strong></td>
<td>Goal</td>
</tr>
<tr>
<td><strong>LDL-C &lt;100 mg/dL</strong></td>
<td>Goal</td>
</tr>
<tr>
<td><strong>If triglycerides are ≥200 mg/dL, non-HDL-C should be &lt;130 mg/dL.</strong></td>
<td>Goal</td>
</tr>
<tr>
<td><strong>PHYSICAL ACTIVITY:</strong></td>
<td>Goal</td>
</tr>
<tr>
<td>30 minutes, 7 days per week (minimum 5 days per week)</td>
<td>Goal</td>
</tr>
<tr>
<td><strong>WEIGHT MANAGEMENT:</strong></td>
<td>Goal</td>
</tr>
<tr>
<td>Body mass index: 18.5 to 24.9 kg/m²</td>
<td>Goal</td>
</tr>
<tr>
<td>Waist circumference: men &lt;40 inches, women &lt;35 inches</td>
<td>Goal</td>
</tr>
</tbody>
</table>

For patients with blood pressure ≥140/90 mm Hg (or ≥130/80 mm Hg for individuals with chronic kidney disease or diabetes):
- As tolerated, add blood pressure medication, treating initially with β-blockers and/or ACE inhibitors, with addition of other drugs such as thiazides as needed to achieve goal blood pressure. I (A)
- [For compelling indications for individual drug classes in specific vascular diseases, see Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7).]

**LIPID MANAGEMENT:**

- Start dietary therapy. Reduce intake of saturated fats (to <7% of total calories), trans-fatty acids, and cholesterol (to <200 mg/dL). I (B)
- Adding plant stanols/stereols (2 g/d) and viscous fiber (>10 g/d) will further lower LDL-C.
- Promote daily physical activity and weight management. I (B)
- Encourage increased consumption of omega-3 fatty acids in the form of fish† or in capsule form (1 g/d) for risk reduction. For treatment of elevated triglycerides, higher doses are usually necessary for risk reduction. IIA (B)

For lipid management:
- Assess fasting lipid profile in all patients, and within 24 hours of hospitalization for those with an acute cardiovascular or coronary event. For hospitalized patients, initiate lipid-lowering medication as recommended below before discharge according to the following schedule:
- LDL-C should be <100 mg/dL. I (A), and
- Further reduction of LDL-C to <70 mg/dL is reasonable. IIA (A)
- If baseline LDL-C is ≥100 mg/dL, initiate LDL-lowering drug therapy.§ I (A)
- If on-treatment LDL-C is ≥100 mg/dL, intensify LDL-lowering drug therapy (may require LDL-lowering drug combination). I (A)
- If baseline LDL-C is 70 to 100 mg/dL, it is reasonable to treat to LDL-C <70 mg/dL. IIA (B)
- If triglycerides are 200 to 499 mg/dL, non-HDL-C should be <130 mg/dL. I (B), and
- Further reduction of non-HDL-C to <100 mg/dL is reasonable. IIA (B)
- Therapeutic options to reduce non-HDL-C are:
  - More intense LDL-C-lowering therapy I (B), or
  - Niacin¶ (after LDL-C-lowering therapy) IIA (B), or
  - Fibrate therapy† (after LDL-C-lowering therapy) IIA (B)
- If triglycerides are ≥500 mg/dL, therapeutic options to prevent pancreatitis are fibrate¶ or niacin¶ before LDL-lowering therapy; and treat LDL-C to goal after triglyceride-lowering therapy. Achieve non-HDL-C <130 mg/dL if possible. I (C)

For all patients:
- Assess risk with a physical activity history and/or an exercise test, to guide prescription. I (B)
- For all patients, encourage 30 to 60 minutes of moderate-intensity aerobic activity, such as brisk walking, on most, preferably all, days of the week, supplemented by an increase in daily lifestyle activities (eg, walking breaks at work, gardening, household work). I (B)
- Encourage resistance training 2 days per week. IIB (C)
- Advise medically supervised programs for high-risk patients (eg, recent acute coronary syndrome or revascularization, heart failure). I (B)

For patients of weight management:
- Assess body mass index and/or waist circumference on each visit and consistently encourage weight maintenance/reduction through an appropriate balance of physical activity, caloric intake, and formal behavioral programs when indicated to maintain/achieve a body mass index between 18.5 and 24.9 kg/m². I (B)
- If waist circumference (measured horizontally at the iliac crest) is ≥35 inches in women and ≥40 inches in men, initiate lifestyle changes and consider treatment strategies for metabolic syndrome as indicated. I (B)
- The initial goal of weight loss therapy should be to reduce body weight by approximately 10% from baseline. With success, further weight loss can be attempted if indicated through further assessment. I (B)

For all patients:
- Ask about tobacco use status at every visit. I (B)
- Advise every tobacco user to quit. I (B)
- Assess the tobacco user’s willingness to quit. I (B)
- Assist by counseling and developing a plan for quitting. I (B)
- Arrange follow-up, referral to special programs, or pharmacotherapy (including nicotine replacement and bupropion). I (B)
- Urge avoidance of exposure to environmental tobacco smoke at work and home. I (B)
- Assess tobacco use status at every visit. I (B)
- Advise every tobacco user to quit. I (B)
- Assess the tobacco user’s willingness to quit. I (B)
- Assist by counseling and developing a plan for quitting. I (B)
- Arrange follow-up, referral to special programs, or pharmacotherapy (including nicotine replacement and bupropion). I (B)
- Urge avoidance of exposure to environmental tobacco smoke at work and home. I (B)
<70-mg/dL target is chosen, it may be prudent to increase statin therapy in a graded fashion to determine a patient’s response and tolerance. Furthermore, if it is not possible to attain LDL-C <70 mg/dL because of a high baseline LDL-C, it generally is possible to achieve LDL-C reductions of >50% with either statins or LDL-C-lowering drug combinations. Moreover, this guideline for patients with atherosclerotic disease does not modify the recommendations of the 2004 ATP III update for patients without atherosclerotic disease who have diabetes or multiple risk factors and a
10-year risk level for CHD >20%. In the latter 2 types of high-risk patients, the recommended LDL-C goal of <100 mg/dL has not changed. Finally, to avoid any misunderstanding about cholesterol management in general, it must be emphasized that a reasonable cholesterol level of <70 mg/dL does not apply to other types of lower-risk individuals who do not have CHD or other forms of atherosclerotic disease; in such cases, recommendations contained in the 2004 ATP III update still pertain.

Trials involving other secondary prevention therapies also have influenced major practice guidelines used to formulate the recommendations in this update. Thus, specific recommendations for clopidogrel use in post–acute coronary syndrome or post–percutaneous coronary intervention–stented patients are now included in this 2006 update. The present update also recommends lower-dose aspirin for chronic therapy. The results of additional studies have further confirmed the benefit of aldosterone antagonist therapy among patients with impaired left ventricular function. Finally, recently published findings of a trial involving angiotensin-converting enzyme inhibitor therapy among patients at relatively low risk with stable coronary disease and normal left ventricular function influenced the recommendations.

The writing group has for the first time added a recommendation with regard to influenza vaccination. According to the US Centers for Disease Control and Prevention, vaccination with inactivated influenza vaccine is recommended for individuals who have chronic disorders of the cardiovascular system because they are at increased risk for complications from influenza.

The writing group emphasizes the importance of giving consideration to the use of cardiovascular medications that have been proved in randomized clinical trials to be of benefit. This strengthens the evidence-based foundation for therapeutic application of these guidelines. The committee acknowledges that ethnic minorities, women, and the elderly are underrepresented in many trials and urges physician and patient participation in trials that will provide additional evidence with regard to therapeutic strategies for these groups of patients.

In the 11 years since the guidelines were first published, 2 other developments have made them even more important in clinical care. First, the aging of the population continues to expand the number of patients living with a diagnosis of cardiovascular disease (now estimated at 13 million for coronary heart disease alone) who might benefit from these therapies. Second, multiple studies of the use of these recommended therapies in appropriate patients, although showing slow improvement, continue to support the discouraging conclusion that many patients in whom therapies are indicated are not receiving them in actual clinical practice. The AHA and ACC recommend the use of programs such as the AHA’s Get With The Guidelines or the ACC’s Guidelines Applied to Practice to identify appropriate patients for therapy, provide practitioners with useful reminders based on the guidelines, and continuously assess the success achieved in providing these therapies to the patients who can benefit from them.

### TABLE 2. Classification of Recommendations and Level of Evidence*

<table>
<thead>
<tr>
<th>Classification of Recommendations</th>
<th>Level of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class I: Conditions for which there is evidence and/or general agreement that a given procedure or treatment is beneficial, useful, and effective.</td>
<td>Level of Evidence A: Data derived from multiple randomized clinical trials or meta-analyses.</td>
</tr>
<tr>
<td>Class II: Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.</td>
<td>Level of Evidence B: Data derived from a single randomized trial or nonrandomized studies.</td>
</tr>
<tr>
<td>Class IIa: Weight of evidence/opinion is in favor of usefulness/efficacy.</td>
<td>Level of Evidence C: Only consensus opinion of experts, case studies, or standard-of-care.</td>
</tr>
<tr>
<td>Class IIb: Usefulness/efficacy is less well established by evidence/opinion.</td>
<td></td>
</tr>
<tr>
<td>Class III: Conditions for which there is evidence and/or general agreement that a procedure/treatment is not useful/effective and in some cases may be harmful.</td>
<td></td>
</tr>
</tbody>
</table>

*Classification of Recommendations and Level of Evidence are expressed in the ACC/AHA format and described in more detail in Table 3.*
## TABLE 3. Applying Classification of Recommendations and Level of Evidence

<table>
<thead>
<tr>
<th>Level</th>
<th>Multiple (3-5) population risk strata evaluated</th>
<th>General consistency of direction and magnitude of effect</th>
<th>Recommended Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level A</td>
<td>• Recommendation that procedure or treatment is useful/effective &lt;br&gt; • Sufficient evidence from multiple randomized trials or meta-analyses</td>
<td>• Recommendation in favor of treatment or procedure being useful/effective &lt;br&gt; • Some conflicting evidence from multiple randomized trials or meta-analyses</td>
<td>Procedure/Treatment SHOULD be performed/administered</td>
</tr>
<tr>
<td>Level B</td>
<td>• Recommendation that procedure or treatment is useful/effective &lt;br&gt; • Limited evidence from single randomized trial or non-randomized studies</td>
<td>• Recommendation in favor of treatment or procedure being useful/effective &lt;br&gt; • Some conflicting evidence from single randomized trial or non-randomized studies</td>
<td>IT IS REASONABLE to perform procedure/administer treatment</td>
</tr>
<tr>
<td>Level C</td>
<td>• Recommendation that procedure or treatment is useful/effective &lt;br&gt; • Only expert opinion, case studies, or standard-of-care</td>
<td>• Recommendation in favor of treatment or procedure being useful/effective &lt;br&gt; • Only diverging expert opinion, case studies, or standard-of-care</td>
<td>Procedure/Treatment MAY BE CONSIDERED</td>
</tr>
</tbody>
</table>

### Suggested phrases for writing recommendations +

- should be recommended
- is indicated
- useful/effective/beneficial
- is reasonable
- can be useful/effective/beneficial
- is probably recommended or indicated
- may/might be considered
- may/might be reasonable
- usefulness/effectiveness is unknown/unclear/uncertain or not well established
- is not recommended
- is not indicated
- should not
- is not useful/effective/beneficial
- may be harmful

*Data available from clinical trials or registries about the usefulness/effectiveness in different sub-populations, such as gender, age, history of diabetes, history of prior MI, history of heart failure, and prior aspirin use. A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Even though randomized trials are not available, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.

†In 2003, the ACC/AHA Task Force on Practice Guidelines developed a list of suggested phrases to use when writing recommendations. All recommendations in this guideline have been written in full sentences that express a complete thought, such that a recommendation, even if separated and presented apart from the rest of the document (including headings above sets of recommendations), would still convey the full intent of the recommendation. It is hoped that this will increase readers’ comprehension of the guidelines and will allow queries at the individual recommendation level.
Appendix

Appendix: References and Supplemental Search Criteria Used to Support Each Recommendation and Level of Evidence

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>References and Supplemental Search Criteria</th>
</tr>
</thead>
</table>
| **SMOKING:**                    | Primary reference(s) used: 2, 3, 21, 22  
Supplemental search done? No                                                   |
| **BLOOD PRESSURE:**             | Primary reference(s) used: 2, 4  
Supplemental search done? Yes  
Database(s) used: PubMed and EMBASE for all English-language human studies  
Key words:  
PubMed: blood pressure OR hypertension AND practice guidelines and/or prevention and/or clinical trial and/or pharmacology  
EMBASE: secondary prevention OR guidelines AND blood pressure AND Cochrane review OR controlled clinical trial OR randomized controlled trial AND pharmacology OR hypertension AND Cochrane review OR controlled clinical trial OR randomized controlled trial AND pharmacology  
Years searched: 2003–March 2005  
Supplemental search did not alter recommendations. |
| **LIPID MANAGEMENT:**           | Primary reference(s) used: 2, 5, 7  
Supplemental search done? Yes  
Database used: PubMed for all English-language human studies  
Key words: cholesterol/lipids/lipoproteins AND clinical trials and/or meta-analysis and/or practice guidelines  
Years searched: 2002–November 2005  
Supplemental search added references 6, 8–12, and 33–37 and altered the recommendations. |
| **PHYSICAL ACTIVITY:**          | Primary reference(s) used: 2, 13–16, 21, 22  
Supplemental search done? No                                                   |
| **WEIGHT MANAGEMENT:**          | Primary reference(s) used: 2, 17–19, 21, 22  
Supplemental search done? No                                                   |
| **DIABETES MANAGEMENT:**        | Primary reference(s) used: 2, 20–22  
Supplemental search done? No                                                   |
| **ANTIPLATELET AGENTS/ANTICOAGULANTS:** | Primary reference(s) used: 2, 21–25, 27, 29  
Supplemental search done? Yes, for use of ASA after CABG  
Database(s) used: PubMed for all English-language studies  
Key words: antiplatelet agents, coronary artery bypass graft patency  
Years searched: 2000–March 2005  
Supplemental search did not alter the recommendations. |
| **RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM BLOCKERS:** | Primary reference(s) used: 2, 21, 22, 27, 28  
Supplemental search done? Yes  
Database used: PubMed for all English-language studies  
Key words: ACE inhibitor or angiotensin receptor antagonist or aldosterone antagonist AND clinical trials and/or meta-analysis and/or practice guidelines  
Years searched: 2003–March 2005  
Supplemental search added references 25 and 30–32 and altered the recommendations. |
| **β-BLOCKERS:**                 | Primary reference(s) used: 2, 21, 22, 27, 28  
Supplemental search done? Yes  
Database used: PubMed for all English-language studies  
Key words: beta blockers AND clinical trials and/or meta-analysis and/or practice guidelines  
Years searched: 2002–March 2005  
Supplemental search did not alter recommendations. |
| **INFLUENZA VACCINATION:**      | Primary reference(s) used: 38  
Supplemental search done? No                                                   |
<table>
<thead>
<tr>
<th>Writing Group Member</th>
<th>Employment</th>
<th>Research Grant</th>
<th>Other Research Support</th>
<th>Speakers Bureau/Honoraria</th>
<th>Ownership Interest</th>
<th>Consultant/Advisory Board</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jerlyn Allen, RN, ScD</td>
<td>Johns Hopkins University, School of Nursing</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>*Board of Directors, Preventive Cardiovascular Nurses Association; Board of Directors, Southeast Lipid Association</td>
<td>None</td>
</tr>
<tr>
<td>Steven N. Blair, PED</td>
<td>Cooper Institute</td>
<td>$HealthTech, $Jenny Craig</td>
<td>None</td>
<td>Donates all honoraria to The Cooper Institute</td>
<td>None</td>
<td>$Mavita, $Life Fitness, $Jenny Craig</td>
<td>All items listed pertain to the Cooper Institute. Does not personally receive money from any of these.</td>
</tr>
<tr>
<td>Robert O. Bonow, MD</td>
<td>Northwestern University, School of Medicine</td>
<td>None</td>
<td>None</td>
<td>*Bristol-Myers Squibb Medical Imaging</td>
<td>None</td>
<td>*Bristol-Myers Squibb Medical Imaging, King Pharmaceuticals</td>
<td>These are no relationship to current writing committee; they are included for completeness.</td>
</tr>
<tr>
<td>Lawrence M. Brass, MD</td>
<td>Yale University</td>
<td>Bristol-Myers Squibb, Sanofi/Synthelabo*</td>
<td>None</td>
<td>Bristol-Myers Squibb, Sanofi/Synthelabo, Solvay Pharmaceuticals, Wyeth</td>
<td>None</td>
<td>AstaZeneaca, Bristol-Myers Squibb, Johnson&amp;Johnson, Merck, GSK Pharmaceuticals, Sanofi/Synthelabo, Solvay Pharmaceuticals, Wyeth</td>
<td>None</td>
</tr>
<tr>
<td>Gregg C. Fonarow, MD</td>
<td>University of California, Los Angeles</td>
<td>$GlaxoSmithKline, $Pfizer, $Medtronic</td>
<td>None</td>
<td>$GlaxoSmithKline, $Pfizer, $Merck–Schering Plough, $Bristol-Myers Squibb–Sanofi, $AstraZeneca, *Wyeth</td>
<td>None</td>
<td>$GlaxoSmithKline, $Pfizer, $Merck–Schering Plough, $Bristol-Myers Squibb–Sanofi, $AstraZeneca, *Wyeth</td>
<td>None</td>
</tr>
<tr>
<td>Loren Hiratzka, MD</td>
<td>TriHealth, Inc</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Daniel Jones, MD</td>
<td>University of Mississippi Medical Center</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Harlan M. Krumholz, MD</td>
<td>Yale University</td>
<td>$CV Therapeutics</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>*CV Therapeutics, $AHA Inc (Consultant), $Tunited Healthcare (Advisory), $TFMC (Clin Coordinator), $MMS (Editorial Board)</td>
<td>None</td>
</tr>
<tr>
<td>Marc A. Pfeffer, MD, PhD</td>
<td>Brigham &amp; Women's Hospital</td>
<td>Aman, Amgen, Novartis, Bristol-Myers Squibb, Sanofi-Synthelabo</td>
<td>None</td>
<td>The Brigham &amp; Women's Hospital has been awarded patents related to the use of inhibitors of the renin-angiotensin system in selected survivors. He is co-inventor. However, the licensing agreement is not linked to sales;</td>
<td>None</td>
<td>*AstraZeneca, *Genzyme, *Takeda, *Mitsubishi, *Abbott, *Aman, *Bristol-Myers Squibb, *CSL, *Novartis, *Sanofi, *Pfizer</td>
<td>None</td>
</tr>
<tr>
<td>Kathryn A. Taubert, PhD</td>
<td>American Heart Association</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

*Modest.
†Significant.

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “Significant” if (a) the person receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “Modest” if it is less than “Significant” under the preceding definition.
<table>
<thead>
<tr>
<th>Reviewer</th>
<th>Employment</th>
<th>Research Grant</th>
<th>Other Research Support</th>
<th>Speakers Bureau/Honoraria</th>
<th>Ownership Interest</th>
<th>Consultant/Advisory Board</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jonathan Abrams, MD</td>
<td>University of New Mexico Health Science Center</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Joseph Alpert, MD</td>
<td>University of Arizona Department of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Jeffrey L. Anderson, MD</td>
<td>LDS Hospital Cardiology (grant pending)</td>
<td>None</td>
<td>Bristol-Myers Squibb, Dia Dexus, Guilford, Merck, Johnson &amp; Johnson, Merck, Merck-Schering, Sandh-Aventis</td>
<td>None</td>
<td>Bristol-Myers Squibb, Dia Dexus, Guilford, Merck, Johnson &amp; Johnson, Merck, Merck-Schering</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Eric R. Bates, MD</td>
<td>University of Michigan Medical Center</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Vera Bilthner, MD</td>
<td>University of Alabama at Birmingham</td>
<td>None</td>
<td>Pfizer, Merck, Kos, Reliant</td>
<td>None</td>
<td>None</td>
<td>CV Therapeutics, Reliant</td>
<td>None</td>
</tr>
<tr>
<td>Ann Bolger, MD</td>
<td>University of California San Francisco</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Roger S. Blumenthal, MD</td>
<td>Johns Hopkins Hospital</td>
<td>Merck, Pfizer</td>
<td>None</td>
<td>Pfizer, Merck, Astra Zeneca, Kos, Schering-Plough</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Prakash Desdwania, MD</td>
<td>University of California San Francisco</td>
<td>Pfizer, AstraZeneca</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Pfizer, AstraZeneca, Novartis</td>
<td>None</td>
</tr>
<tr>
<td>Mark J. Eisenberg, MD</td>
<td>McGill University</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Gerald Fletcher, MD</td>
<td>Mayo Clinic</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Alan D. Forker, MD</td>
<td>St. Lukes Hospital</td>
<td>Pfizer, Merck, Kos, Novartis, Sanofi, Bristol-Myers Squibb</td>
<td>None</td>
<td>Pfizer, Merck, Takeda</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Timothy Gardner, MD</td>
<td>Clinical Practices of the University of Pennsylvania</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Cindy L. Grimes, MD</td>
<td>William Beaumont Hospital</td>
<td>Berlex, Pfizer, GlaxoSmithKline, Aventis, Guidant Bi-Lilly, SCIMED, Johnson &amp; Johnson, Amersham Health, Otsuka, Esperion Therapeutics, Innercool Therapies, AstraZeneca</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Innercool Therapies, Pfizer, Sanofi-Synthelabo, Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, GlaxoSmithKline Global Cardiovascular Advisory Board</td>
<td>None</td>
</tr>
<tr>
<td>Suzanne Hughes, MSN, RN</td>
<td>None</td>
<td>None</td>
<td>Kos Pharmaceuticals</td>
<td>None</td>
<td>Guidant Corporation, Johnson &amp; Johnson Merck</td>
<td>Freelance writer—honoraria paid by the ACCF; Associate Editor, Circulation</td>
<td>None</td>
</tr>
<tr>
<td>Edgar J. Kenton, MD</td>
<td>Lankenau Hospital</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Marian Limacher, MD</td>
<td>University of Florida</td>
<td>Boehringer Ingelheim</td>
<td>NIH, NHLBI</td>
<td>Kos Pharmaceuticals</td>
<td>None</td>
<td>NIH Advisory Committee on Research on Women’s Health</td>
<td>None</td>
</tr>
<tr>
<td>Jonathan R. Lindner, MD</td>
<td>University of Virginia</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Janet B. Long, MSN, ACNP</td>
<td>University Cardiology Foundation</td>
<td>None</td>
<td>None</td>
<td>AstraZeneca</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Patrick McBride, MD</td>
<td>University of Wisconsin Medical School</td>
<td>None</td>
<td>None</td>
<td>Kos, Merck, Pfizer, Sanofi, Schering Plough</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dale Owen, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Riba F. Redberg, MD, MSc</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Samuel J. Shubrooks, Jr, MD</td>
<td>Harvard Medical School</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Robert A. Vogel, MD</td>
<td>University of Maryland Hospital</td>
<td>Pfizer, Novartis, Schering-Plough</td>
<td>None</td>
<td>Pfizer, Merck</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit.
References


